Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
Yabuuchi H et al. | Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. | 1991 | Transplant. Proc. | pmid:1703718 |
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. | 1991 | Transplant. Proc. | pmid:1721253 | |
Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
Takaya S et al. | Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. | 1991 | Transplant. Proc. | pmid:1721348 |
Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
de Paulis A et al. | Characterization of the anti-inflammatory effect of FK-506 on human mast cells. | 1991 | J. Immunol. | pmid:1721644 |
van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
Tze WJ et al. | Long-term survival of islet allografts in diabetic rats treated with FK 506. | 1991 | Transplant. Proc. | pmid:1721411 |
Wang X et al. | Intraportal FK 506 improves intrahepatic islet allograft survival. | 1991 | Transplant. Proc. | pmid:1721412 |
Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
Hasegawa S et al. | FK 506 and cyclosporine: effects and side effects in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721443 |
Wada H et al. | Dose response to FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721444 |
Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
Sakai K et al. | The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. | 1991 | Brain Res. | pmid:1723023 |
Weaver JL et al. | Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. | 1991 | Immunopharmacol Immunotoxicol | pmid:1723084 |
Burres NS et al. | Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. | 1991 | J. Antibiot. | pmid:1723403 |
Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |